StockData

Fulgent Genetics vs RadNet

FLGT and RDNT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FLGT and RDNT compare

RadNet is the larger company, worth 8.9 times as much as Fulgent Genetics ($6.0B against $679M).

RadNet grew revenue faster over the last twelve months (21.1% versus 4.7% for Fulgent Genetics).

RadNet keeps more of each dollar of sales as profit, with a net margin of −0.94% compared with −27.5% at Fulgent Genetics.

Fulgent Genetics scores higher on the StockData Score (8 against 7 for RadNet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFLGTRDNT
Size and price
Market cap$679M$6.0B
Share price$24.66$76.42
Change, 1 year−15.2%2.6%
Change, 5 years−73.8%170%
Beta (5Y)0.891.15
Employees1,30076
StockData Score
Total score8 (better)7
Valuation score3 (better)0
Growth score02 (better)
Performance score12 (better)
Health score4 (better)3
Dividend score00
Valuation
P/S2.1× (better)2.5×
P/B0.7× (better)5.4×
EV/EBITDA–27.4×
FCF yield−0.21%–
Fair value$46.08$48.94
Margin of safety46.5% (better)−56.1%
Growth
Revenue growth (TTM)4.7%21.1% (better)
Revenue growth, 5Y average−5.2%13.7% (better)
Profitability
Gross margin33.8%–
Operating margin−39.2%3.1% (better)
Net margin−27.5%−0.94% (better)
FCF margin−0.42%–
Return on equity−8.6%−2.1% (better)
Return on invested capital−12.0%2.8% (better)
Financial health
Debt / equity0.00 (better)1.18
Net debt / EBITDA–2.28
Interest coverage−1307.9×1.0× (better)
Current ratio5.34 (better)1.49
Altman Z-score5.18 (better)1.94
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield9.5%–
Shareholder yield9.5% (better)0.00%
Ownership
Held by institutions57.0%104%
Held by insiders39.5%4.6%
Insider net buying, 12 months−$286K (better)−$11.9M
Short interest, % of float12.1%11.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.